Search Results for: Global Cancer Vaccine Market to
Articles
Global Cancer Vaccine Market to Reach $4.3 Billion in 2019 January 13, 2015
BCC Research recently announced in its new report, Cancer Vaccines: Technologies and Global Markets, the global market for cancer vaccines...PHARMACEUTICAL GLOBALIZATION - Navigating Opportunities & Obstacles December 4, 2023
Jürgen Hönig says rapid globalization of the pharmaceutical industry has created new complexities as companies navigate different regulations and government policies, but there are many reasons for optimism, including harmonization, collaboration, and convergence.
Oxford Biomedica Signs Agreement to Acquire ABL Europe, Consolidating Position as a Global Pure-Play CDMO December 4, 2023
Oxford Biomedica plc recently announced it has entered into a sale and purchase agreement with TSGH SAS, a subsidiary of Institut Mérieux SA, for the acquisition of….
Pfizer & BioNTech Announce Positive Topline Data for mRNA-Based Combination Vaccine Program Against Influenza & COVID-19 October 26, 2023
Pfizer Inc. and BioNTech SE recently announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability, and immunogenicity...Aptamers Market is Expected to Reach $342 million April 27, 2023
The aptamers industry has been growing steadily in recent years, and is expected to continue to do so in the...Pfizer Invests $43 Billion in Seagen Acquisition to Battle Cancer March 14, 2023
Pfizer Inc. and Seagen Inc. recently announced they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash….
MARKET REPORT - Survey Suggests Global Innovation to Recover Much More Quickly Than Expected in 2023 February 9, 2023
After a brief fall in 2022 to a score of 6.5 – the first decline since its inception in 2018 – the index has surged to a record score of 7.4. This sudden recovery in scores over a little more than 8 months bodes extremely well for device and packaging manufacturers in the year ahead, suggesting a strong global recovery in industry outlook and confidence.
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer June 23, 2022
Evaxion Biotech A/S recently announced it has selected EVX-03 as the product candidate within its DNA technology platform to target...NEC & Shionogi Enter Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine April 18, 2022
NEC Corporation and Shionogi & Co., Ltd. recently announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic….
Evonik Increases Global Supply of Pharma-Grade Plant-Derived Cholesterol for mRNA Vaccines & Gene Therapies March 4, 2022
Evonik has boosted its supply of plant-derived cholesterol, one of the most critical components for the manufacture of mRNA vaccines and gene therapies. The large-scale production of….
Exclusive License for Croda to Commercialize SSI’s CAF® Vaccine Adjuvants March 3, 2022
Croda International Plc, which uses smart science to improve lives, recently announces it has entered a strategic collaboration with Statens...MARKET LANDSCAPE - The Future of Cancer Care Post-Pandemic: What Doctors, Patients, and the Healthcare Industry at Large Should Expect March 1, 2022
Angelos Stergiou, PhD, explains how the COVID-19 pandemic saw failures in the healthcare delivery system not only in general medicine, but also specifically in oncology. At the same time, several opportunities came to light during such a difficult, frightening moment, bringing a number of large- and small-scale innovations forth.
POP Biotechnologies Vaccine Technology to Enter Phase 3 Clinical Studies as Part of Eubiologics' COVID-19 Vaccine Candidate, EuCorVac-19 February 7, 2022
POP Biotechnologies recently announced the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine...Pfizer & BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine January 5, 2022
Pfizer Inc. and BioNTech SE recently announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles….
Pfizer & BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine October 21, 2021
Pfizer Inc. and BioNTech SE recently announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of...Terumo Blood & Cell Technologies & PhotonPharma Inc. Announce Collaboration to Develop Novel Cancer Immunotherapy August 17, 2021
Terumo Blood and Cell Technologies and PhotonPharma Inc. recently announced they have established a memorandum of understanding (MOU) for collaboration to develop Innocell, a novel….
Dyadic & Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate & C1 Technology for Protein-Based Coronavirus Vaccines & Therapeutics August 17, 2021
Dyadic International, Inc. and Sorrento Therapeutics, Inc. recently announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for….
SPECIAL FEATURE - PFS & Parenteral Manufacturing: How COVID-19 Changed the Market May 3, 2021
Contributor Cindy Dubin explores how device developers and parenteral contract development and manufacturing organizations (CDMOs) are addressing current challenges, as well as advancements in customized device design, the continuous effort to incorporate safety and human factors, and how COVID-19 is shaping the future of the market.
Agenus Submits Balstilimab Biologics License Application to the US FDA for Patients With Recurrent or Metastatic Cervical Cancer April 21, 2021
Agenus Inc. recently announced the submission of a Biologics License Application (BLA) to the US FDA for the accelerated approval of….
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-Based COVID-19 Vaccine Candidate April 21, 2021
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. recently announced initiation of a rolling submission for CVnCoV, the company’s mRNA-based COVID-19 vaccine….
